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Abstract
Interferon-gamma (IFN-c) inhibits intracellular replication of Francisella tularensis in human monocyte-derived macrophages
(HMDM) and in mice, but the mechanisms of this protective effect are poorly characterized. We used genome-wide RNA
interference (RNAi) screening in the human macrophage cell line THP-1 to identify genes that mediate the beneficial effects
of IFN-c on F. tularensis infection. A primary screen identified ,200 replicated candidate genes. These were prioritized
according to mRNA expression in IFN-c-primed and F. tularensis-challenged macrophages. A panel of 20 top hits was further
assessed by re-testing using individual shRNAs or siRNAs in THP-1 cells, HMDMs and primary human lung macrophages. Six
of eight validated genes tested were also found to confer resistance to Listeria monocytogenes infection, suggesting a
broadly shared host gene program for intracellular pathogens. The F. tularensis-validated hits included ‘druggable’ targets
such as TNFRSF9, which encodes CD137. Treating HMDM with a blocking antibody to CD137 confirmed a beneficial role of
CD137 in macrophage clearance of F. tularensis. These studies reveal a number of important mediators of IFN-c activated
host defense against intracellular pathogens, and implicate CD137 as a potential therapeutic target and regulator of
macrophage interactions with Francisella tularensis.
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Introduction
Francisella tularensis is a highly virulent, facultative intracellular
bacterium that causes tularemia [1,2]. F. tularensis is considered a
potential bioweapon, in part because it is extraordinarily
infectious, requiring inoculation or inhalation of as few as 10
bacteria to cause disease. Historical details of episodic outbreaks,
possible military applications and bioterrorism implications are
reviewed in [3]. Given the limitations of current vaccines and
therapies, novel diagnostic and treatment modalities are needed,
but progress has been stymied by a lack of knowledge about key
pathogenic and host defense mechanisms.
The natural history of infections caused by F. tularensis offers a
promising clue. Macrophages are the main site of replication of F.
tularensis [4], and lung macrophages are especially targeted in
inhalational tularemia [5]. F. tularensis infection of macrophages
has been studied in vitro, where bacterial growth can produce more
than 1,000 fold replication [6]. Intracellular killing of F. tularensis
by macrophages depends on IFN-c-induced activation [7,8,9], but
the specific mechanisms of IFN-c induced killing are not fully
understood. Inducible nitric oxide synthase (iNOS) and NADPH
phagocyte oxidase contribute to the antimicrobial activity of
murine macrophages [10,11], however, there is some controversy
surrounding their importance [12,13]. There is considerable
discordance in different experimental systems, reflecting variable
responses of macrophages from different species and sites
[13,14,15] and the use of different conditions by different
laboratories. Furthermore, there are important differences be-
tween human and rodent responses to F. tularensis, including
macrophage cytokine responses [15] and comparative mortality
versus immunization seen with the partially attenuated F. tularensis
live vaccine strain (LVS) [14]. More recent data implicates
autophagy [16,17] and inflammasomes [18,19,20], although the
importance of these in the specific context of IFN-c stimulation
has not been demonstrated. Human macrophages show potent
antibacterial function once ‘‘activated’’, but the genes responsible
for this desirable trait are unknown. We hypothesized that IFN-c
limits intracellular pathogen F. tularensis by activation of specific
genes, and that functional genomic screening could identify these
genes.
The human macrophage cell line THP-1 provides a useful
model for studies of F. tularensis intracellular pathogenesis and
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bacteriostatic/killing mechanisms for intracellular pathogens
[7,8,9]. To identify these IFN-c- induced genes involved in
resistance to intracellular F. tularensis, we performed a genome-
wide RNA interference screen in THP-1 cells. THP-1 cells stably
transduced and expressing shRNAs were phorbol-12-myristate
acetate (PMA) differentiated, activated by IFN-c, and infected
with F. tularensis live vaccine strain (LVS) expressing green
fluorescent protein (GFP) [21]. Infected THP-1 macrophages
were sorted by green fluorescence and the top 1% isolated to
enrich for cells in which shRNA knockdown blocked the ability of
IFN-c-induced genes to inhibit GFP-LVS proliferation. From this
screen, 212 candidate genes and ESTs were identified, of which
168 were selected for expression analysis by real-time PCR array,
both before and after infection, in three different models of IFN-c
activated human macrophages: THP-1 cells, human monocyte-
derived macrophages, and primary human alveolar macrophages,.
A panel of 20 genes (top hits of interest) was further subjected to
functional validation by specific siRNA or lentivirus-mediated
shRNA knockdown. Our results identified several ‘druggable’
genes as potential therapeutic targets, and new leads to host
defense mechanisms. We further tested one top ‘‘hit,’’ the receptor
CD137 (TNFRSF9) in detail, using a blocking anti-CD137
receptor antibody, and confirmed its function in human
macrophage clearance of F. tularensis.
Results
Interferon-c activated THP-1 macrophages inhibit
intracellular replication of F. tularensis
We first tested our assumption that IFN-c activation would
enable the human macrophage cell line THP-1 to inhibit
intracellular replication of F. tularensis. THP-1 cells were
differentiated by PMA, followed by pre-treatment with IFN-c
(100 U/ml) for 24 h, and the cells were infected with green
fluorescent protein labeled F. tularensis LVS (GFP-LVS) as
described in Methods. After 4 h and 24 h infection, the growth
of GFP-LVS was examined by colony forming unit (CFU) assay
(Fig. 1A). At 4 h after infection the number of intracellular
bacteria in IFN-c-activated THP-1decreased relative to control
Figure 1. IFN-c-activated THP-1 cells inhibit intracellular replication of F. tularensis. Quiescent (control) and IFN-c-activated (100 U/ml)
THP-1 cells were incubated for 2 h with GFP-expressing F. tularensis LVS, followed by 30 min gentamicin treatment to kill extracellular bacteria, and
subsequent determination of the number of intracellular bacteria at 4 h and 24 h post-infection by (A) colony forming unit (CFU) assay. Multiplicity of
infection (MOI) was 10:1 (bacteria: macrophage). *P,0.05 compared to control. Data were pooled from three independent experiments and
presented as mean6SD. (B) Representative images showing the number of intracellular GFP-LVS after 24 h infection by fluorescence microscopy
(4006). MOI=40:1. (C) Quantification of the intracellular GFP-LVS bacteria after 24 h infection (MOI=40:1) by flow cytometry, with axes set to the
same scales for all groups and10,000 cells counted per sample. Gray histograms represent uninfected cells. Green histograms represent cells infected
with GFP-LVS, and overlap between the two in dark green.
doi:10.1371/journal.pone.0031752.g001
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IFN-c-activated THP-1 cells was approximately 20 times lower
than observed in the unactivated (control) THP-1 cells at low MOI
of 10 bacteria per macrophage. CFU assay indicated that bacterial
replication was completely inhibited in IFN-c-activated THP-1
macrophages. This result was confirmed by fluorescence micros-
copy and flow cytometry at 24 h post-infection (Fig. 1B and
Fig. 1C), in which the green fluorescence of intracellular bacteria
was markedly lower in IFN-c treated THP-1 cells compared to
control cells. The effect of IFN-c is concentration dependent over
the dose range of 20–500 U/ml (data not shown). These results
verified the expected beneficial IFN-c effect and its ability to limit
F. tularensis LVS growth in the PMA-differentiated THP-1
macrophages.
Preparation of human macrophage cell line THP-1 pool
with genome-wide lentiviral shRNA library
In order to optimize transduction of the GeneNet
TM lentiviral
shRNA library into THP-1 cells we evaluated transduction
efficiency of control viral particles over a range of virus titers
using the two available expression systems (FIV- and HIV-based)
from System Biosciences (SBI). THP-1 cells were transduced with
copGFP by positive control lentiviral particles and transduction
efficiency was assessed by fluorescence microscopy (Fig. S1A and
S1B) and flow cytometry (Fig. S1C) 4 days post-transduction.
Percent transduction increased with multiplicity of infection
(MOI), but MOIs of 20 or greater resulted in substantial cell
death. At virus titers of 10–15 per macrophage, transduction
efficiency was greater with the FIV-based (80%–86%) than with
the HIV-based (52%–71%) expression system (Fig. S1C), and
caused minimal cell death. Based on these results we selected the
FIV-based vector and a viral titer of 10 for subsequent screen
transductions. The average number of lentiviral constructs
integrated into the genomic DNA of each transduced cell was
estimated using the SBI Lentivector Rapid Titer PCR Kit. By
comparing the quantity of vector-specific WPRE amplified from a
sample of our transduced cells with that from the SBI calibration
standard (Fig. S1D) we estimated an MOI for our screen
transduction of ,1.3, which, based on control data provided by
SBI (Fig. S1D, lower panel), corresponded to a transduction
efficiency of ,75%, approximating the value predicted from the
copGFP transduction data (Fig. S1C).
Flow cytometric sorting to screen for genes that mediate
the effect of IFN-c on macrophage killing of F. tularensis
Our strategy and protocol for the genome-wide screen is
outlined in Figure 2. Following transduction of THP-1 cells with
human 50K shRNA lentiviral library, transduced THP-1 cells
were differentiated with PMA and pre-treated with IFN-c, then
infected with green fluorescent F. tularensis LVS for 2 h. Cells were
then washed and treated with gentamicin to remove or kill
extracellular bacteria, and incubated for 24 hours. Cells trans-
Figure 2. Protocol used for genome-wide RNAi screen: sorting for high GFP-positives. Step 1: construct THP-1 library cells by transduction
of human THP-1 macrophage cell line with GeneNet
TM Human 50 k shRNA library. Step 2: differentiate THP-1 library cells with PMA, and activate the
cells with IFN-c. Step 3: infect the library cells with GFP-labeled F. tularensis live vaccine strain (GFP-LVS). Step 4: harvest cells at indicated time points,
and fix the cells for biosafety prior to flow cytometry. Step 5: FACS sorting to isolate small population of cells with the highest green fluorescence
(containing the most GFP-LVS). Step 6: identify siRNA targets and genes by PCR, cloning and DNA sequencing.
doi:10.1371/journal.pone.0031752.g002
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involved in the beneficial bactericidal effect of IFN-c would be less
able to prevent bacterial growth, so carry a higher load of F.
tularensis, and thus exhibit higher green fluorescence. These cells
were collected by FACS and their genomic DNA isolated. Target
shRNA sequences were amplified from the lentiviral constructs
integrated into the genomic DNA by PCR, and subcloned and
expanded in E. coli to produce samples for sequencing, as detailed
in materials and methods.
The results of five independent screens and FACS sorts were
analyzed. Frequency analysis was used to identify genes of interest.
We focused on the genes that appeared multiple times within an
experiment, and placed the greatest emphasis on genes that
appeared in multiple independent experiments, reasoning that
biologically significant ‘hits’ would appear repeatedly and
multiply, whereas single hits would likely be false positives
resulting from noise within the system. Using this rationale, we
identified top hits for further validation based on the following
results. A total of 4078 sequences (740, 756, 960, 764 and 858,
respectively) were obtained from the five independent sorts. From
these, 3386 genes and ESTs were identified. Repeat hits
(appearing in more than one screen) were found in the following
frequencies: $2 sorts: 212 hits; $3 sorts: 61 hits; 4 sorts: 2 hits. In
addition to hits identified in two or more screens, we included in
our genes of interest 35 single hits, corresponding to genes that
were very similar, albeit non-identical (but usually closely related),
to genes that did appear in two or more screens. The rationale for
including these genes is that if knockdown of functionally similar
genes, differing slightly in minor sequence components, is observed
repeatedly, then those genes or their products may belong to a
functional group that constitutes a potentially valid target. The
final list of 247 genes of interest is shown in Table S1.
To further analyze the top 212 human genes found in 2 or more
independent screens in our primary RNAi screen that potentially
affect F. tularensis proliferation, these genes were uploaded into the
Ingenuity Pathway Analysis (IPA) software (http://www.ingenuity.
com), and canonical pathways were determined as described
previously [22,23,24]. This analysis identified 110 hits with
Molecular and Cellular Functions (Fig. S2A), 135 hits involved
in Diseases and Disorders (Fig. S2B), and 52 hits associated with
Physiological System Development and Function (Fig. S2C). In
addition, 150 of the identified genes were found to be involved in
ten networks (Fig. 3A), suggesting functional linkages among
clusters of genes identified by our screen. There are limitations to
this approach, since many genes cross over into multiple
categories. Nevertheless, oOne of these networks includes 16
molecules in the category ‘Hematological Disease, Immunological
Disease, and Cell Death’ and includes TNFRSF9 which may be
Figure 3. Network Analysis. (A) Top hits involved in ten significant networks identified by Ingenuity pathway analysis. The numbers surrounding
the pie charts represent the number of the top hits involved in each network. (B) 16 hits (highlighted in green) are in a network linked to a category
designated as ‘hematological disease, immunological disease, cell death’, which includes TNFRSF9/CD137. Connection lines 33, represent direct
interactions; ----, represent indirect interactions.
doi:10.1371/journal.pone.0031752.g003
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(Fig. 3B). TNFRSF9 is also known as CD137 which is further
discussed below.
Validation of target gene expression in human lung
macrophages by qPCR
We selected a subset of the top 168 gene hits, shown in Table 1,
for further validation. The primary criterion for selection was
frequency: all hits found in 4 and 3 sorts, and most of those found
in 2 sorts were included. Also included were a small number of
genes of interest identified in parallel efforts using our EST-based
library (e.g. pleckstrin, unpublished data) that were in the same
functional area (e.g., intracellular trafficking) as other hits in the
shRNA library screens. The choice of 168 hits in part also reflects
the number of genes that could be analyzed per plate in the
custom array platform used (84 per plate, see Methods).
Expression of putative gene hits was measured in macrophages
to test the prediction that these genes would, at a minimum, be
expressed, and would likely exhibit increased expression after IFN-
c pretreatment, and/or after IFN-c pretreatment followed by F.
tularensis challenge (consistent with the observed biological effect of
their knockdown). Three types of macrophages were used in these
experiments: PMA-differentiated THP-1 macrophages, human
monocyte-derived macrophages, differentiated to be ‘alveolar-
macrophage’-like [25], and primary human alveolar macrophages
(AMs). The 168 gene expression levels in IFN-c-induced
macrophages were compared to those in control cells without
IFN-c activation. The results of quantitative PCR from these
studies are summarized in Figure 4A and Figure 4B. In THP-1
macrophages basal or induced expression was seen for the
majority of the original hits with IFN-c activation (a fold change
of $1.5 was set as the threshold for gene up-regulation).
Numerous hits were also expressed differentially by HMDMs
and primary human AMs. Ten genes were identified with
overlapping expression changes in all three cell types. These are
shown in Figure 4C and detailed in Table 2. These results confirm
the importance of comparing results with the useful but imperfect
cell line model (THP-1) to actual primary cells.
Functional validation of top 20 hits with lentiviral shRNA
or siRNA knockdown
Our next goal in validation was to test whether we could
reproduce the functional phenotype selected originally by the
screening assay. If these genes are truly important functionally,
then individual knockdown should replicate the screen – namely,
cause loss of antibacterial capacity and allow growth of
intracellular F. tularensis. We used two complementary approaches.
The first was to obtain commercially-available individual lentiviral
shRNA preparations targeting the genes, transduce THP-1 cells,
select transductants with puromycin and establish pools of
lentiviral transduced cells. Using this approach, we first tested
whether the lentiviral shRNA was having its expected effect of
reducing gene expression. Figure 5A shows the results with 3
different sequences against one target, TNFRSF9, and in this case
we observed satisfactory reduction of gene expression (50%–60%)
with all 5 shRNAs tested. Similar gene knockdown was observed
for SERPINI1 with 5 different lentiviral shRNAs. We have tested
F. tularensis bacterial growth within subcloned individual knock-
down lines from THP-1 cells transduced with these shRNAs. The
flow cytometry data show that knockdown of the gene targets
TNFRSF9 and SERPINI1 does have the predicted effect of
increasing bacterial content, despite IFN-c activation of the
macrophages (Fig. 5B). In these experiments we initially used a
green fluorescent F. tularensis and measured intracellular bacterial
content after 24 h infection by flow cytometry. This type of
knockdown validation has been successful for all 5 of the first set of
top hits (TNFRSF9, CLNS1A, RARRES1, SERPINI1 and
TRIM10). We have also been able to validate these findings
further by bacterial CFU assays. The results of CFU assay for
TNFRSF9 clone D and SERPINI1 clone 1 showed increased
Table 1. Top 168 genes chosen for expression analysis by
qRT-PCR arrays.
ABCC4 ENPP4 MYBPC1 SERPINB7
ABCC9 EP300 N4Bp2L2 SERPINI1
ABHD2 F2RL1 NAP1L2 SFRS5
ACSL4 FABP4 NCBP1 SH2B3
ACTR2 FAF1 NDUFA9 SIRT1
ADAM30 FLRT3 NPY5R SIRT4
ADAM9 FXN NRP1 SLC11A2
ADAMTS1 GAD2 PCDH11Y SLC25A13
ADD2 GCSH PCDHA1 SLC25A46
ADD3 GDNF PDCD4 SLC4A4
AIFM1 GNG13 PDCL SLC4A7
ALDH2 GPX3 PDHX SNAPC3
AP2S1 GRM1 PEX1 SSX3
APC HIST1H1D PEX11A STRN3
AQP4 HIVEP1 PEX12 STX3
ATG16L1 HLA-DRB1 PICALM STXBP5L
ATG5 HNRPH2 PLCB2 SULT1C2
ATP2B4 HNRPK PLEK2 SYNC1
ATP6V1D HSD3B2 PLS1 TAOK1
BAG4 IFNB1 PLS3 TCF7
BDNF ITGA5 PLXNC1 TEP1
BIRC3 ITGA6 PPFIA1 TFPI2
CACNA1D ITPR1 PRF1 TGOLN2
CALM1 ITPR3 PSIP1 TIA1
CASP8 KATNB1 PTBP2 TLL2
CCL8 KCND2 PTPRA TM2D2
CD58 KIF4A PTPRF TNFRSF6B
CDC42EP4 KLF11 RAB11FIP2 TNFRSF9
CEACAM8 LCP2 RAB11FIP3 TRIM10
CEBPB LEPR RAB31 TRIM49
CHN2 LGI1 RAPGEF2 TRPA1
CLN3 LHCGR RARRES1 TSHR
CLN5 LRBA RECQL TTC9
CLNS1A M6PRBP1 REL TUBB1
CSNK1G2 MAP4K4 RFC5 TUBB2C
CUL4B MCL1 RPL31 UBE2E3
DICER1 MED12 SCARB1 UGT2B17
DKC1 MED6 SCGB2A2 ZFR
DMXL2 MLLT10 SCN3B ZNF193
EGFR MPZL1 SEC24D ZNF228
EIF2AK2 MTDH SEMA3G ZNF263
EML1 MTF2 SERPINA7 ZNF638
doi:10.1371/journal.pone.0031752.t001
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SERPINI1 genes were knocked down by shRNAs (Fig. 5C).
Further functional evaluation of top hits was performed using
liposome-based transfection of macrophages with individual
siRNAs. This simpler delivery method allows validation testing
in days, compared to the several weeks required to create stably
transduced knockdowns, and also allows testing of non-replicating,
terminally differentiated cells (e.g. HMDMs). Figure 6A illustrates
one example of effective target (TNFRSF9) expression knockdown
using this method. In this case expression of TNFRSF9 mRNA
was reduced by ,60% and ,70% at 48 h and 72 h, respectively.
Figure 6B demonstrates that THP-1 macrophages transfected with
Figure 4. Gene expression validation of top 168 hits. Custom human qRT-PCR arrays (Array 1, top 84 hits;Array 2, top 85–164 genes) were used
to measure gene expression in three human macrophages (THP-1 cell line, human monocyte-derived macrophages, and human primary AMs) with or
without IFN-c activation, and with or without F. tularensis LVS infection for 24 hours (MOI=40:1). All gene expression was normalized to three human
housekeeping genes, ACTB, GAPDH and NONO. (A & B) Heat map showing IFN-c–induced gene expression changes among top 84 (A) and 85–164 (B)
hits in the three types of IFN-c-activated macrophages 6 LVS (left and right columns) compared to control cells without IFN-c treatment. Green
indicates lower, and red, higher expression. (C) Venn diagram of genes up-regulated in the three types of IFN-c activated macrophages with and
without F. tularensis challenge. Ten genes showed induced expression in all three macrophages.
doi:10.1371/journal.pone.0031752.g004
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TNFRSF9 can reproduce the screening phenotype (reversal of the
IFN-c effect, with increased intracellular F. tularensis proliferation),
confirming that TNFRSF9 acts to inhibit F. tularensis proliferation
in activated macrophages. Because liposomal transfection can be
performed in non-dividing cells, we were also able to validate hits
in primary HMDMs. Figure 6C shows that HMDMs transfected
with siRNAs targeting TNFRSF9 and SERPINI1 failed to control
F. tularensis growth, despite IFN-c treatment. The combined results
of validation using lentiviral shRNAs and siRNAs in THP-1 cells
and primary HMDMs are summarized in Table 3. The top 20
‘hits’ shown in this table constitute a group of novel potential
therapeutic targets. As shown in Table 4, existing modulating
agents are already available for a subset of these targets, providing
a direct means for investigating the potential benefit of targeting
these genes or their products in F. tularensis infections.
Validation of top hits with virulent F. tularensis strain
The regulatory and logistical challenges associated with using
fully virulent, select agent strains of F. tularensis make use of such
strains impractical for studies requiring extensive molecular
biology. We therefore chose to perform the majority of this study
using the attenuated model Live Vaccine Strain F. tularensis LVS,
and to confirm key findings with fully a virulent strain, SchuS4. As
expected, IFN-c inhibited intracellular growth of SchuS4 in THP-
1 cells, though not completely as LVS. After 24 h infection, IFN-c-
activated THP-1 cells had 60% lower virulent bacterial growth
than quiescent THP-1 cells (Fig. 7A). Then we evaluated virulent
F. tularensis SchuS4 infection of THP-1 cells in which six top hit
genes (TNFRSF9, SERPINI1, HLA-DBR1, PLEK2, ATG5 and
ATG16L1) were knocked down by individual lentiviral shRNA. At
24 h post-infection, knockdown of TNFRSF9 and SERPINI1
reversed the ability of IFN-c to restrict survival of F. tularensis
SchuS4 in THP-1 cells, as shown by CFU assay (Fig. 7B). Similar
results were seen for the other genes tested, except PLEK2 (data
not shown). These results suggest top hits identified using LVS are
also relevant to virulent F. tularensis infection.
Top hits mediate resistance to other intracellular
pathogens
To determine whether the IFN-c benefit conferred or mediated
by our top hit genes is specific to F. tularensis infection or functions
more generally in response to intracellular pathogens, we
investigated the effect of 8 of the top hit genes from our screen
(TNFRSF9, SERPINI1, SERPINA7, HLA-DRB1, ATG5,
ATG16L1, PLEK2 and PLS1) on Listeria monocytogenes infection
in THP-1 cells stably transduced with shRNAs targeting these
genes. Interestingly, at 20 h post-infection, six of the eight (all but
PLEK2 and PLS1) also showed reversal of IFN-c mediated
resistance to L. monocytogenes infection, as illustrated in Figure 8 for
THP-1 cells with TNFRSF9 and SERPINI1 gene knockdown.
Novel role of CD137 in macrophage clearance of
F. tularensis
We sought to further explore the role of the gene identified in
our screen as TNFRSF9, which encodes CD137. CD137 and its
ligand, CD137L, are transmembrane modulatory proteins ex-
pressed on many immune cell types, and comprise a bi-directional
signaling system, wherein CD137L initiates signaling through
CD137, and vice versa [26,27,28]. We used a blocking
monoclonal antibody to test the prediction that blocking this
surface receptor would also reproduce the findings with our RNAi
screen: namely, an increase in intracellular bacterial proliferation
despite IFN-c activation. As seen in Figure 9, both flow cytometry
and scanning cytometry (9A–9D) show increased content of GFP-
LVS in HMDMs treated with blocking anti-CD137 monoclonal
antibody compared to IgG1 or no treatment controls. Measure-
ment of viable LVS bacteria in cell lysates gave similar results
(Fig. 9E). Our results demonstrate that CD137 can modulate
clearance of F. tularensis, providing additional confirmation of this
target initially implicated in the RNAi screen.
Discussion
New therapies and countermeasures against biological warfare
agents are needed, but progress has been stymied by a lack of
knowledge about key pathogenic mechanisms. The natural history
of infections caused by intracellular bacterial pathogens, e.g.
Francisella tularensis [3,4,14,29], offers a promising clue. Macro-
phages–the main cellular target of F. tularensis—can develop the
ability to kill the intracellular invaders after ‘activation’ by immune
mediators, e.g. interferon-c [13,30,31,32]. Identification of the
mechanisms and genes responsible for this beneficial transforma-
tion might provide a treasure trove of novel therapeutic targets,
but this goal has not been met using traditional approaches.
The goal of this study was to identify novel therapeutic targets
for infections caused by F. tularensis. The specific strategy was to
use genome-wide shRNA interference to identify genes that
mediate the beneficial, but poorly understood, effects of IFN-c.
Table 2. Top 10 genes with increased expression in all 3 human macrophage types.
Gene Identity Function
TNFRSF9 NM_001561 Tumor necrosis factor receptor superfamily 9
CLNS1A NM_001293 Chloride channel, nucleotide-sensitive, 1A
RARRES1 NM_206963 Retinoic acid receptor-responsive gene
SERPINI1 NM_005025 Serpin (serine or cysteine) proteinase inhibitor, clade I (neuroserpin) member 1
TRIM10 NM_052828 Tripartite motif-containing 10 isoform 1 and 2
CCL8 NM_005623 Small inducible cytokine A8 precursor
ENPP4 NM_014936 Ectonucleotide phyrophosphatase/phosphodiesterase 4 (putative function)
F2RL1 NM_005242 Coagulation factor II (thrombin) receptor-like 1
RAPGEF2 NM_014247 Rap guanine nucleotide exchange factor 2
HLA-DRB1 NM_002124 MHC class II HLA-DR beta 1 or 4 chain
doi:10.1371/journal.pone.0031752.t002
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for studies of F. tularensis intracellular pathogenesis, and reproduces
the key response of interest, activation by IFN-c of bacteriostatic/
killing mechanisms for intracellular pathogens [7,8,9]. We used an
optimized protocol to transduce THP-1 cells with the GeneNet
TM
Human 50K shRNA Library, and generated a library of THP-1
cells with a different shRNA expression construct in every cell.
The main advantage of this strategy is the possibility of creating a
very high complexity genome-wide shRNA library of all genes
including some ESTs, with application of global loss-of-function
genetic screen for unbiased discovery of genes involved in specific
phenotypes.
Using this lentiviral shRNA-based loss-of-function screen for the
THP-1 library, we were able to identify and sort IFN-c-activated
macrophages that failed to limit intracellular growth of green
fluorescent F. tularensis [21]. Repeated screens and sorts allowed us
to identify by sequencing the shRNAs which were enriched in
multiple experiments (Table S1). These initial hits were further
evaluated and validated by gene expression analysis, and
functional testing using individual lentiviral constructs and
siRNAs. Validation steps included use of different targeting
sequences, since the possibility of off-target effects is well-known
for RNAi. We were able to functionally replicate increased
bacterial proliferation upon knockdown of the top 20 genes
Figure 5. Validation of TNFRSF9 and SERPINI1 gene expression and function. (A) qPCR analysis of expression of TNFRSF9 and SERPINI1
genes in THP-1 macrophages after transduction with individual lentiviral shRNAs compared to controls transduced with non-targeting shRNA. PCR
reactions were normalized against b-actin and plotted relative to expression levels in control cells. Error bars indicate6 SD of triplicates. (B) Flow
cytometry analysis of the effect of lentiviral shRNA knockdown of TNFRSF9 and SERPINI1 genes on F. tularensis GFP-LVS infection after 24 h in THP-1
cells 6 IFN-c, 40 U/ml. Controls were transduced with non-targeting shRNA. Quantification of GFP-LVS bacteria at 24 h post-infection (MOI=82:1) is
shown by green fluorescence histograms, using identical scale axes for all groups; uninfected cell green fluorescence histograms are shown in gray,
GFP-LVS infected cell histograms in light green, and overlap between the two in dark green. (C) CFU assay results of the effect of lentiviral shRNA
knockdown of TNFRSF9 and SERPINI1 genes on GFP-LVS infection in THP-1 cells 6 IFN-c, 40 U/ml at 24 h (MOI=82:1). Control THP-1 cells were
transduced with non-targeting shRNA. Mean 6 SD, *P,0.05 compared to control+IFN-c group.
doi:10.1371/journal.pone.0031752.g005
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macrophage-like monocyte-derived macrophages and normal
human lung macrophages to allow focus on genes functional in
primary cells.
GFP-labeled F. tularensis Live Vaccine Strain was an ideal tool
which permitted a strategy to do our screening and analysis under
BL2 conditions. Although we used GFP-labeled F. tularensis LVS in
our initial RNAi screen, most of a subset tested (5 of 6 genes)
exhibited resistance to both LVS and a virulent F. tularensis strain
(Fig. 5B and 5C, Fig. 7B). These data now support the value of
undertaking future studies under more complex and demanding
BL3 conditions. In addition, several top hits were tested with
another intracellular pathogen, Listeria monocytogenes, and our results
revealed that these IFN-c induced beneficial genes (TNFRSF9,
SERPINI1, SERPINA7, HLA-DRB1, ATG5, and ATG16L1)
were also functional relevant to Listeria infection (Fig. 8), consistent
with shared host response mechanisms to both intracellular
pathogens, F. tularensis and L. monocytogenes. It will be interesting
to test these gene functions in other intracellular pathogens
including Mycobacterium tuberculosis.
We succeeded in identifying numerous novel genes involved in
control of F. tularensis by activated macrophages. The results are
the list of potential therapeutic targets tabulated in Table 3. Among
the more promising of these are the top five targets shown in
Table 4, which are considered to be ‘druggable’ [33,34,35,36,
37] (http://www.openbiosystems.com/RNAi/shRNAmirLibraries/
GIPZLentiviralshRNAmir/HumanDruggablesubset/) or potentially
modulated by existing pharmacologic or therapeutic agents. In
addition to providing the list oftherapeutic targets, our research has
established the utility of the functional screening approach for drug
target identification in bioterrorism infectious agents. It is especially
noteworthy that the top potential target gene product, TNFRSF9,
is also known as CD137 [28,38,39], a receptor target that is
presently being investigated in human clinical trials using a
humanized monoclonal antibody that acts as an agonist. CD137
has been identified as a novel and potent monocyte activation
factor [26], and it promotes adherence and prolongs survival of
human peripheral monocytes by inducing a strong expression of
macrophage colony-stimulating factor, an essential monocyte
survival factor [28]. We found that CD137 knockdown with a
blocking anti-CD137 antibody resulted in markedly increased
bacterial load in human monocyte-derived macrophages (Fig. 9A–
E), reproducing the phenotype that led to its identification in our
screen. Ingenuity pathway analysis suggested that TNFRSF9/
CD137 may interact with NF-kB, Akt, P38 MAPK and IL12
signaling pathways. Future studies with CD137 agonists are
warranted to test their potential beneficial effect in F. tularensis
infection, and more studies will be needed to elucidate the
mechanism of CD137 clearance of F. tularensis in macrophages.
In summary, this genome-wide functional screen identified
numerous novel genes that may help activated macrophages
control intracellular replication of Francisella. Our validation efforts
addressed a partial subset, and generally confirmed the initial
findings of the RNAi screen. Although additional validation of the
genes tabulated is needed, this data set provides ample leads for
future investigation.
Materials and Methods
Reagents
Phorbol-12-myristate acetate (PMA), hexadimethrine bromide
(Polybrene), penicillin/streptomycin, gentamicin, puromycin, am-
picillin, human AB serum, MISSIONH lentiviral transduction
particles were purchased from Sigma-Aldrich, recombinant
human interferon-gamma (IFN-c) and human granulocyte/
macrophage-colony stimulating factor (GM-CSF) from Pepro-
Tech, DNeasy Blood & Tissue Kit, DNaseI, RNeasy Mini Kit,
siRNAs and HiPerFect transfection reagent from Qiagen, and
PureLink
TM Quick Gel Extraction Kit, PureLink
TM Quick
Plasmid Miniprep Kit, TOPO TA Cloning, TRIZOL reagent,
and CellMask
TM Blue and Hoechst 33342 dyes from Invitrogen
(Life Technologies). RT
2 First Strand kit, RT
2 profiler
TM PCR
arrays, RT
2 qPCR Primers, and RT
2 SYBRH Green/ROX qPCR
Master Mix were obtained from SABiosciences. Anti-CD137
mouse monoclonal (clone 4B4) was purchased from BioLegend,
and mouse IgG1 isotype control antibodies from Sigma-Aldrich.
Culture of macrophages
Human monocyte-like THP-1 cells were obtained from the
American Type Culture Collection. THP-1 cells were cultured in
Figure 6. Validation of TNFRSF9 and SERPINI1 gene expression and function with gene knockdown by siRNA. (A) Comparison of
TNFRSF9 gene expression using qPCR assay after treatment of THP-1 cells with 100 nM specific or control siRNA for 48 hours and 72 hours. (B) Flow
cytometry analysis of siRNA TNFRSF9 knockdown in THP-1 cell with F. tularensis GFP-LVS infection for 24 h. THP-1 macrophages were treated with
50 nM or100 nM of siRNA for 72 h, and pre-activated with IFN-c (40 U/ml) overnight prior to GFP-LVS infection (MOI=35:1). Y-axis represents mean
green fluorescence level (GFL). *P,0.05 compared to control Ctr_siRNA+IFN-c group. (C) Flow cytometry analysis of GFP-LVS infection for 24 h in
HMDMs following 100 nM siRNA knockdown of TNFRSF9 and SERPINI1, respectively. *P,0.05 compared to control Ctr_siRNA+IFN-c group.
doi:10.1371/journal.pone.0031752.g006
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with 10% fetal bovine serum, 2 mM L-glutamine, 100 U/ml
penicillin, 100 mg/ml streptomycin, 50 mM2 - b-mercaptoethanol,
1 mM sodium pyruvate) at 37uCi n5 %C O 2.
Human alveolar-like peripheral blood monocyte-derived mac-
rophages (HMDMs) were prepared as previously described [25].
Primary human alveolar macrophages (AMs) were obtained by
bronchoalveolar lavage from healthy human volunteers and
cultured in RPMI complete media for 2 days before infection.
Human cell samples were collected after obtaining written
informed consent and were approved by institutional review
boards at Harvard School of Public Health and Beth Israel
Deaconess Medical Center, respectively.
Transduction of THP-1 cells with shRNA library
We used the GeneNet
TM Human 50 k shRNA Library from
System Biosciences Inc (SBI) for this screen. The library contains
,200,000 siRNA templates targeted to 47,400 human transcripts
listed in the NCBI RefSeq database, packaged in a Feline
Immunodeficiency Virus (FIV)-derived vector, pSIF1-H1-Puro.
The packaged library was transduced into THP1 cells according to
the manufacturer’s recommendations. Four days after transduc-
tion, the number of shRNA constructs per macrophage was
determined using SBI’s Lentivector Rapid Titer PCR Kit,
according to the manufacturer’s protocol. GFP expression in
THP1 cells transduced with a GFP reporter construct (pSIF1-H1
siLuc-copGFP, SBI) was used to construct a calibration standard
for this assay. Transduced macrophages were selected with
puromycin (1 mg/ml) for 9–10 days.
Growth of F. tularensis and macrophage infection
F. tularensis subsp. holoarctica live vaccine strain (LVS) with
plasmid pKK214GFP/ASV [21] coding for green fluorescent
protein was generously provided by Dr. Larry S. Schlesinger (Ohio
State University, Columbus, Ohio). Bacteria were grown to
logarithmic phase in Modified Mueller-Hinton broth with
tetracycline (10 mg/ml) and aliquots stored at 280uC. Before
each infection experiment, the bacteria were thawed, streaked on
Cystine Heart agar plates enriched with 1% hemoglobin and
containing tetracycline for 1 day at 37uC. Bacteria were then
suspended in PBS at an optical density of ,0.405 at 600 nm,
corresponding to 3610
9 bacteria/ml. Virulent F. tularensis subsp.
tularensis strain SchuS4 was grown and used in the New England
Regional Centre of Excellence in Biodefense and Emerging
Infectious Diseases at Harvard Medical School. 24 h prior to
infection, bacteria were streaked onto hemoglobin-enriched
Cystine Heart agar plates and grown at 37uC. Bacteria were then
suspended in PBS and concentration estimated by optical density.
To increase uptake of F. tularensis by macrophages, both LVS and
virulent strains were opsonized with 10% fresh human AB serum
in PBS for 30 min at 37uC [21], [40], then diluted with RPMI
medium containing 10% human AB serum to the desired MOI
prior to infection. Macrophage infections were performed at the
MOIs listed in the figure legends. Bacterial densities were
confirmed by plating dilutions of inolcula and counting colonies.
THP-1 cells, HMDMs, and primary human AMs were
subjected to the same general bacterial infection protocol, with
some variations. THP-1 cells and THP-1 shRNA library cells were
seeded in 6-well tissue culture plates at a density of 8610
5 cells per
Table 3. Summary of functional validation results for top
candidates.
Gene Target
THP-1+lentiviral
shRNA THP-1+siRNA HMDM+siRNA
TNFRSF9 ++ ++ ++
SERPINI1 ++ ++ ++
TRIM10 ++ ++ ++
HLA-DRB1 ++ ++ ++
PLEK2 ++ ++ ++
PLS1 ++ ++ +
ATG5 ++ ++ ++
ATG16L1 ++ ++ ++
SERPINA7 ++ ++ +
SERPINB7 ++ 2 +
RAPGEF2 ++ + 2
F2RL1 ++ + 2
ENPP4 ++ + 2
CCL8 ++ + 2
CLN5 ++ NT NT
CLNS1A NT ++
NAP1L2 2 ++ +
RARRES1 NT + 2
LCP2 NT + 2
SLC4A7 NT 2 +
Note: Following shRNA or siRNA knockdown of the target genes, IFN-c
pretreated THP-1 and HMDM cells were infected with F. tularensis GFP-LVS.
After 24 hours, the intracellular GFP-LVS was measured by flow cytometry and
compared to control. Results are summarized as ++, GFP greater than control by
$40%; +, GFP greater than control by $20%; 2, GFP greater than control by
,20%. NT, not tested.
doi:10.1371/journal.pone.0031752.t003
Table 4. Top 5 hits as therapeutic leads.
Gene Protein ‘Druggable’ Genome? Therapeutics?
TNFRSF9 tumor necrosis factor receptor superfamily, member 9 YES Agonist monoclonal (anti-CD137) in clinical trials [35]
SERPINI1 serpin peptidase inhibitor, clade I member 1 YES Related serine protease family inhibitors used
clinically (aprotinin, A1AT)
RARRES1 retinoic acid receptor responder YES Up-regulated by tazarotene [36], FDA-approved drug
CLNS1A chloride channel, nucleotide- sensitive, 1A YES Multiple chloride channel enhancing drugs for CF [37]
TRIM10 tripartite motif-containing 10 YES Zinc/metal binding domain suggests chelator
function; chelators picolinic acid, desferal in clinical
use
doi:10.1371/journal.pone.0031752.t004
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Medium containing PMA was then removed and cells were
incubated for overnight in fresh medium with IFN-c. HMDM cells
and primary human AMs were seeded at 1610
6 cells/well in 6-
well plates for 2 days prior to infection. At time of infection cells
were washed with warm RPMI without antibiotics, and 2 ml of
RPMI/10% human AB serum with opsonized F. tularensis was
added to each well. Cells were infected at an MOI of ,40:1 in all
screens. The plates were then centrifuged at 9006g for 20 minutes
and incubated for 2 hours at 37uC with 5% CO2. Cells were then
washed with fresh media, and incubated for 30 min at 37uC with
media containing gentamicin (50 mg/ml) to kill any extracellular
bacteria. Cells were washed again and cultured in RPMI/10%
FBS medium for 24 hours at 37uCi n5 %C O 2.
Culture of Listeria monocytogenes
L. monocytogenes strain 10403S expressing green fluorescent
protein (s-gfp/pPL3) was generously provided by Dr. Darren E.
Higgins (Harvard Medical School, Boston, MA). The L.
monocytogenes-GFP were grown in brain heart infusion medium
containing 7.5 mg/ml of chloramphenicol (GFP plasmid selection
agent) for 15–18 h at 30uC without shaking. Macrophages were
infected using a protocol similar to that described for F. tularensis.
CD137 antibody blocking F. tularensis phagocytosis by
HMDMs. All reagents and buffers were at room temperature
when added to cells, and all incubations were performed at 5%
CO2 and 37uC, unless otherwise specified. HMDMs were
suspended at 4610
5/ml in RPMI/10% FBS and dispensed into
black-walled 96 well BD-Falcon Imaging plates (BD Biosciences) at
1.0610
5 cells/well, or 6-well cell culture plates at 1.0610
6 cells/
well, and incubated for 24 h to become adherent. Cells were then
incubated overnight with fresh RPMI/10% FBS containing either
5.0 mg/ml anti-CD137 antibody, 5.0 mg/ml IgG1 isotype control
or no treatment. HMDMs were infected with suspensions of LVS-
GFP, at 2.0610
9 CFU/ml in RPMI/0.3% BSA (total volume
100 ml/well for 96-well plates and 1.5 ml/well for 6-well plates) for
2 h, then incubated for 30 min with gentamicin in RPMI/10%
FBS to kill extracellular bacteria, washed three times with PBS to
remove gentamicin, incubated overnight with fresh RPMI/10%
FBS containing treatments as detailed above, and processed as
described below for flow cytometry, scanning cytometry, and CFU
quantification.
Flow cytometry
Human macrophages infected or uninfected with green
fluorescent protein labeled bacteria were analyzed using a
FacsCanto II flow cytometer (BD Biosciences). At the indicated
time points post-infection, supernatants from 6-well plates were
aspirated and HMDMs were harvested using 0.25% Trypsin-
EDTA (to harvest THP-1, 0.01% Typsin-EDTA was used). The
Figure 7. Validation of TNFRSF9 and SERPINI1 genes using virulent F. tularensis. (A) IFN-c-activated THP-1 cells inhibited SchuS4 growth at
4 h and 24 h infection. IFN-c, 40 U/ml (SchuS4, MOI=30:1). (B) CFU assay of TNFRSF9 and SERPINI1 shRNA knockdown THP-1 macrophages infected
with SchuS4 strain. Control (THP-1 cells transduced with negative control lentiviral shRNA), TNFRSF9 knockdown cells (clone D) and SERPINI1
knockdown cells (clone1) were infected with virulent SchuS4 strain for 24 h (MOI=30:1). *P,0.05 compared to +IFN-c group.
doi:10.1371/journal.pone.0031752.g007
Figure 8. Effect of TNFRSF9 and SERPINI1 knockdown on
Listeria growth in THP-1 macrophages. Flow cytometry analysis of
THP-1 macrophages (transduced with TNFRSF9 and SERPINI1 shRNA or
non-target control shRNA) 20 hours following infection with GFP-
Listeria (MOI=150:1). Y-axis indicates mean green fluorescence index
(GFL). *P,0.05 compared to Non-target shRNA+IFN-c group.
doi:10.1371/journal.pone.0031752.g008
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PBS for 10 min, then washed once with PBS, and resuspended in
PBS. 10000 cells were analyzed for each sample for green
fluorescence.
Scanning cytometry
Cells in black-walled 96-well plates were fixed by incubation
with 4% formaldehyde for 10 minutes at room temperature,
washed twice with PBS, incubated with HBSS/2.5 mg/ml HCS
CellMask Blue cytoplasmic stain and 2 mg/ml Hoechst nuclear
stain, washed twice with PBS, and finally covered with PBS.
Confocal fluorescence microscopy was performed using a BD
Pathway 855 High-Content Bioimager with a 206 NA075
objective. Collapsed confocal stack GFP channel images (GFP-
expressing F. tularensis) were acquired using 470/40 band-pass (BP)
excitation, 515 long-pass (LP) dichroic and 515/30 BP emission
filters. Single confocal Hoechst nuclear/CellMask Blue cytoplas-
mic label images were acquired using 350/50 BP excitation, 400
LP dichroic, 435 LP emission filters. Sufficient image fields were
collected from duplicate wells to provide a minimum of 500 cells
for quantitative analysis of each sample condition. Image analysis
and quantification was performed to quantify average number of
bacteria/cell using our custom MATLABH (The Mathworks,
Natick, MA) software [41].
Bacterial CFU assay
Macrophages were lysed in 1 ml (per well of a 6-well dish) of
PBS containing 0.1% Saponin at room temperature for 10 min.
Lysates were serially diluted in PBS, and 100 ml of each dilution
was spread on Cystine Heart agar/1% Hemoglobin plates. The
Figure 9. CD137 modulates clearance of F. tularensis. Adherent HMDMs were pre-treated with anti-CD137 antibody or isotype control prior to
infection with F. tularensis GFP-LVS, and analyzed for bacterial load at 2 h and 24 h by flow cytometry, scanning cytometry and CFU assay. (A) Flow
cytometry fluorescence histograms for a single experiment at 2 and 24 h. Gray histograms represent uninfected cells. Green histograms represent
cells infected with GFP-LVS. (B) Representative scanning cytometry images of GFP-LVS-containing HMDMs at 24 h post infection. (C–E) Quantitative
results at 2 h and 24 h for (C) flow cytometry (N=4), (D) scanning cytometry (N=5), and (E) CFU assay (N=3). *P,0.05, **P,0.01, ** P,0.001
(symbols directly above bars indicate significance relative to untreated control; symbols between bars indicate significance between the two bars
indicated by horizontal lines).
doi:10.1371/journal.pone.0031752.g009
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used to calculate the number of bacteria in the original cell lysates.
FACS sorting of target cells
Following transduction with the GeneNet
TM human 50 K
shRNA library, PMA-differentiation, IFN-c-activation, and incu-
bation with GFP-LVS for 24 h, THP-1 cells were harvested and
sorted using the BD FACS Aria sorting flow cytometer in the
Brigham & Women’s Hospital Core Facility (Boston, MA).
Appropriately 200 K to 300 K cells with the highest green
fluorescence signal (top 1%) were collected from the pool of
infected cells in each screen experiment (‘‘sort’’). Although it is
possible that siRNAs may target GFP or bacterial gene expression
without inhibiting bacteria, this is a concern for screens that rely
on decreased expression; in contrast, our screen was designed to
identify increased GFP content.
Genomic DNA extraction and total RNA isolation
Total genomic DNA was isolated and purified from sorted
target cells using the Qiagen DNeasy Blood and Tissue Kit.
Approximately 1–4 mg total genomic DNA was obtained from
each FACS sort. Total RNA was isolated using TRIzol Reagent.
RNAs were further cleaned up by using RNeasy Mini kit with
DNase I treatment to improve the quality of the final RNA
samples.
Identification of shRNA inserts by PCR Amplification,
cloning and DNA sequencing
shRNA inserts from the target cells were amplified from
genomic DNA (isolated from sorted cells) in two rounds of PCR
using 2 sets of primers. The first round of PCR was performed
using the primers provided with the shRNA library kit from SBI,
referred to as the Fwd GNF Primer and the Rev GNF Primer. The
second round of PCR was performed using primers referred to as
Fwd 37: 59-CGTGAAAT GTCTTTGGATTTGGG-39, and
SBI’s Rev Nested Primer: 59-AAAGAATGCTTATGGACGC-
TAGA-39. The products from the first round of PCR were used as
the templates for the second round. After the second round of
PCR, the products were run on a 2.5% agarose gel and purified
using the PureLink Quick Gel Extraction Kit. The purified PCR
products were then cloned into competent E. coli DH5a-T1R
using the TOPO TA Cloning Kit. White clones grown on LB/
Ampicillin (100 mg/ml) and X-gal selective plates were picked for
DNA sequencing at the Dana Farber/Harvard Cancer Center
DNA Resource Core. DNA sequences were analyzed using
Sequencer 4.8 software from Gene Codes Corporation. This
software allowed us to identify the shRNA inserts within sequence
by comparing the known plasmid sequences on either side of the
target shRNA inserts within the pSIF1-H1 vector. The shRNA
target sequences were then subjected to a BLAT (http://www.
genome.ucsc.edu/) search to identify the corresponding targeted
genes based on sequence similarity. More than 70% of total
genes/transcripts/ESTs were identified using BLAT search. In
cases in which, as a result of the high stringency of the BLAT
program (requiring over 90% identity), a gene was not found, the
sequence was subjected to BLAST search (www.ncbi.nlm.nih.gov/
blast), which matches genes to sequences with the closest match.
Validation using PCR arrays
Expression of mRNA for the top 168 genes from our primary
screen was evaluated using custom PCR arrays from SABioscience
Inc, according to the manufacturer’s recommended protocol, and
using their software. Expression levels were obtained and
evaluated for three macrophage types (THP-1, HMDMs, and
primary AMs) under 4 conditions (with or without IFN-c
activation, and with or without F. tularensis LVS infection).
Duplicate samples (in duplicate plates) were tested for each cell
type and condition, and expression levels were normalized against
those of housekeeping genes using the recommended algorithm.
Expression level data were compared across the three cell types to
identify gene candidates with shared expression for further
functional validation. Heat maps showing 168 gene expression
levels in macrophages with IFN-c activation versus without IFN-c
induction were generated using Eisen Lab Cluster Analysis and
Visualization Software (http://www.eisenlab.org/eisen/).
Validation using lentiviral shRNA and siRNA
Each MISSION
TM lentiviral particle pool (Sigma) consisted of
an average of 3–5 individual shRNA constructs targeting different
regions of each gene sequence. MISSION Non-target shRNA
control transduction particles were used as a negative control. For
stable expression experiments, THP-1 cells were plated at 5610
5/
well in a 12-well plate in 1 ml of DMEM complete medium.
Polybrene was added to the cells at a final concentration of 6 mg/
ml, and viral particles were added at an MOI of 1. The cell-viral
particle mixture was incubated at 37uC overnight followed the
procedure provided by Sigma. On day 3, the medium was
replaced with fresh complete medium containing 1 mg/ml
puromycin for selection of transduced cells. Puromycin-containing
medium was replaced every 3–4 days until resistant colonies could
be identified. For each target gene at least 5 puromycin-resistant
colonies were picked and expanded to be assayed for knockdown.
In transient expression experiments, PMA-differentiated THP-1
macrophages and HMDMs were transfected with FlexiTube
siRNAs using HiPerFect transfection reagent (Qiagen). Ctr_All-
Stars_1 siRNA from Qiagen was used as a negative control. THP-
1 cells were seeded at 400 K cells/well in 6-well plates in RPMI
complete medium containing 100 nM PMA, and HMDM cells
were seeded at 200 K cells/well in RPMI complete medium. Cells
were incubated at 37uCi n5 %C O 2 for 24 hrs. Shortly before
transfection, the culture medium was removed and replaced with
500 ml fresh RPMI complete medium, and the cells were returned
to normal growth conditions. To create transfection complexes,
100 nM siRNA in RPMI without additives (total 500 ml) was
incubated with 12 ml of HiPerFect transfection reagent for
10 minutes at room temperature. The complexes were added
drop-wise onto the cells. Cells were incubated with the transfection
complexes for 6–8 hours at 37uC in 5% CO2. 0.8 ml of RPMI
complete medium was then added to each well and cells were
incubated for 48 hours prior to bacterial infection assay as per
above.
Statistical analysis
All data were analyzed with Prism software 4.0 (GraphPad),
using paired two-tailed Student’s t tests to determine significance
between groups unless otherwise specified. Differences between
groups were considered statistically significant when the P value
was ,0.05. Unless otherwise indicated, at least three independent
experiments were included in each analysis and the results were
represented as means 6 s.d.
Supporting Information
Figure S1 Optimizing transduction with lentiviral
shRNA library. Fluorescent microscopy imaging copGFP-
positive THP-1 cells after transduction with pSIF1- H1-siLuc-
copGFP (FIV-based) (A) or with pSIH1-copGFP (HIV-based) (B)
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and 20. (C) Comparison of THP-1 cell transduction efficiency with
FIV-based and HIV-based positive transduction control. Flow
cytometry assay was performed to measure the % of GFP positive
cells, which indicates the transduction efficiencies of THP-1. (D)
Determining the % of THP-1 cells infected with GeneNetTM
Human 50 k siRNA library. MOI (multiplicity of infection) is the
average copy number of lentiviral expression constructs per
infected cell. The MOI in transduced cells was determined by
comparison of WPRE gene expression in transduced THP-1
library cells with the Calibration Standard (MOI) using Lenti-
vector Rapid Titer PCR kit. **The table was provided by SBI
based on the percentage of GFP-positive cells in their results to
determine the MOI.
(TIF)
Figure S2 Functional categories of top 212 hits using
Ingenuity pathway analysis. The numbers on the pie charts
represent the number of target genes within each functional
category. (a) 110 Hits in Molecular and Cellular Functions. (b) 135
Hits in Diseases and Disorders. (c) 52 Hits in Physiological System
Development and Function.
(TIF)
Table S1 Results of flow cytometric screening are tabulated
according to the number of sorts and the number of clones in
which a target gene was identified by sequencing. The table lists
results for the 247 gene targets identified in two or more screens of
the total of five conducted.
(PDF)
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